Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Anticancer Res
; 35(12): 6941-50, 2015 Dec.
Article
en En
| MEDLINE
| ID: mdl-26637920
ABSTRACT
AIM:
To evaluate factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer (MBC) in clinical practice in Spain. PATIENTS ANDMETHODS:
All consecutive adult female patients with HER2-negative MBC who had received first-line bevacizumab plus chemotherapy for at least 3 months were enrolled in the present study.RESULTS:
A total of 292 evaluable patients were included; 25% had triple-negative breast cancer (TNBC) and 75% had hormone receptor-positive breast cancer (HRPBC). Nearly 40% of patients had ≥3 metastatic sites, mainly located in the bone (48%) and liver (40%). Bevacizumab was mostly combined with paclitaxel (67.1%). ER-positive tumors were only identified as an independent factor associated with the choice of treatment (odds ratio (OR) 0.538; p=0.02). The overall response rate (ORR) was 63.7% (TNBC 57.5%; HRPBC 65.9%). Patients aged 36-50 years (OR 3.03; p=0.028) and those with metastases at sites other than the bone (OR 0.38; p=0.001) and ≥3 metastatic sites (OR 1.41; p=0.018) were more likely to achieve objective responses.CONCLUSION:
First-line bevacizumab plus chemotherapy, mainly paclitaxel, is an effective and well-tolerated treatment option for HER2-negative MBC, particularly in more aggressive disease.Palabras clave
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptor ErbB-2
/
Bevacizumab
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Anticancer Res
Año:
2015
Tipo del documento:
Article
País de afiliación:
España